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Available online 14 November 2015Placebo analgesia is measured by self-report, yet current, expected, and recalled efficacy may be differentially
related to brain function. Here we used a human thermal pain model to compare self-reports of expected,
concurrent, and recalled efficacy of a topical placebo analgesic, and tested associations of the three measures of
efficacy with changes in dopamine D2/D3 receptor availability in brain using [18F]fallypride with positron
emission tomography (PET). Participants (15 healthy women) were assessed on three test days. The first test
day included a laboratory visit, during which the temperature needed to evoke consistent pain was determined,
placebo analgesia was induced via verbal and experience-based expectation, and the placebo response was
measured. On two subsequent test days, PET scanswere performed in Control and Placebo conditions, respective-
ly, in counterbalanced order. During Visit 1, concurrent and recalled placebo efficacy were unrelated; during the
Placebo PET visit, expected and recalled efficacy were highly correlated (ρ=0.68, p= 0.005), but concurrent ef-
ficacywas unrelated to expected or recalled efficacy. Region of interest analysis revealed dopamine D2/D3 recep-
tor availability was lower in left ventrolateral prefrontal cortex in the Placebo condition (p b 0.001, uncorrected),
and greater change in thismeasurewas associatedwith higher levels of recalled analgesic efficacy (ρ=0.58, p=
0.02). These preliminary findings underscore the need to consider how self-reported symptom improvement is
assessed in clinical trials of analgesics and suggest that dopaminergic activity in the ventrolateral prefrontal
cortex may promote recalled efficacy of placebo.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Placebo effect
Pain
PET
[18F]fallypride
Ventrolateral prefrontal cortex1. Introduction
Clinical outcomes across a broad range of disorders are influenced by
placebo effects. Self-reported symptom improvement is a common
measure of the placebo response, particularly among patients with
chronic pain disorders, which often lack biologically based measuresenheimer Family Center for
avid Geffen School of Medicine
e, Los Angeles, CA 90095-7378,
. This is an open access article underof disease severity (Farrar et al., 2001; Von Korff et al., 1992). In chronic
pain patients, subjective symptoms of pain are the leading cause for
health care utilization (Andersson et al., 1999; Von Korff et al., 1991)
and the basis for perceived success of treatment (Dworkin et al., 2008;
Turk et al., 1993). Isolating biological mechanisms that mediate discrete
forms of self-reported placebo analgesia may help minimize placebo
effects in the context of clinical trials, or maximize them in the context
of clinical management of chronic pain.
The subjective experience of pain is shaped bymany factors, including
mood and affect, expectations, prior sensory information, and the subse-
quent appraisal of this information (Senkowski et al., 2014).
Neuroimaging studies have suggested that placebo analgesia involvesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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prefrontal cortex (PFC), brain regions commonly implicated in regulating
expectations and reappraising outcomes (see meta-analysis by Amanzio
et al., 2013). This heightenedengagement in brain regions thatmay inhib-
it the experience of pain through cognitive mechanisms, is often coupled
with diminished activity in the insula and striatum, brain regions com-
monly implicating in indexing the actual experience of pain (see meta-
analysis by Amanzio et al., 2013). Using positron emission tomography
(PET), we have previously shown that, among patients with a pain disor-
der, placebo analgesia is associated with heightened functional activity in
ventrolateral PFC (vlPFC) (Lieberman et al., 2004). Other PET studies have
shown that endogenous opioid release in regions of the PFC and striatum
also mediate placebo analgesia (Pecina et al., 2014; Wager et al., 2007;
Zubieta et al., 2005, 2006). More recently, dopamine release in the stria-
tum has been linked to placebo effects in Parkinson's disease (de la
Fuente-Fernández et al., 2002, 2001; Kim et al., 2008; Lidstone et al.,
2010; Strafella et al., 2006) and placebo analgesia (Scott et al., 2007,
2008). Such studies of dopamine release have not been extended to
extrastriatal brain regions, leaving open the question of how extrastriatal
dopaminergic function may contribute to placebo analgesia. Moreover,
despite the role of dopamine in shaping expectations, concurrent experi-
ence, and memory (Schultz, 1998; Wise, 2004), whether distinct aspects
of self-report are differentially related to subjective efficacy of placebo and
to dopaminergic function has not been fully explored (Pecina et al., 2014).
Finally, overlapping psychological processes, related to expectation, con-
current experience and memory, have important roles in shaping a
wide range of placebo effects (e. g., Benedetti et al., 2003; Leuchter
et al., 2014; Price et al., 1999). Thus, distinct self-reportedmeasures of pla-
cebo analgesia may vary in magnitude, which in turn may be related to
dopaminergic function.
To address these issues, we assessed self-reports of expected,
concurrent, and recalled placebo analgesia using a thermal pain
model. We used [18F]fallypride, a high-affinity D2/D3 dopamine
receptor ligand (Mukherjee et al., 1995, 2002), with PET to quantify
striatal and extrastriatal receptor binding as participants underwent a
sustained pain challenge with and without a topical placebo analgesic.
We hypothesized that placebo effects would vary in magnitude,
depending on type of self-report measurement. The dopamine system
has consistently been linked with pain processing and placebo effects;
therefore, we hypothesized that D2/D3 dopamine-receptor availability
in the striatum and vlPFC would be lower in the placebo condition,
reflecting enhanced endogenous dopamine release. As distinct brain
regions that comprise the dopamine system may influence a variety of
mechanisms implicated in the appraisal subjective experiences, we
also hypothesized that dopamine release would be differentially related
to discrete self-reported measures of placebo analgesia.
2. Materials and methods
2.1. Subjects
Fifteen young women (mean ± SD: 24.33 ± 3.11 years) completed
the study. Participants were medication-free, right-handed, nonsmokers
with no current or lifetimemajormedical illnesses. The SCID-I/NPwas ad-
ministered to confirm the absence of current and lifetime psychiatric dis-
orders (DSM-IV-TR, Axis I or II). Participants underwent a urine drug
screening at the beginning of each visit to confirm that they were drug-
free. Visits were scheduled to occur during the follicular phase of each
participant'smenstrual cycle, andwere re-scheduled as needed to accom-
modate cycle irregularity. On each testing visit, participants reported the
first day of her last cycle, and provided a saliva sample to test if estradiol
and progesterone levels were consistent with the follicular phase of her
cycle. Participants gave written informed consent prior to enrollment,
and at the conclusion of the study, were fully debriefed regarding the
use of deception. The institutional review board of the University of Cali-
fornia, Los Angeles approved all aspects of the study.2.2. Experiment overview
Procedures were modified from a well-established paradigm in
which placebo analgesia is induced via verbal and experience-based
expectations of pain relief (Wager et al., 2004). Participants were told
that the goal of the study was to evaluate how the brain responds to
thermal stimulation when it is paired with topical application of either
a pain-relief medication or a control liquid that does not contain medi-
cation. The Placebo was identified as Lidocaine, a powerful topically
active, liquid analgesic. The Control was identified as water, which
would not affect pain but otherwise would provide a sensory experi-
ence similar to that of the purportedly active medication. In actuality,
both Placebo and Control liquids were water; no active medication was
used. The experimenter wore a white coat, applied the Placebo and
Control liquids with sterile, cotton-tipped applicators, from amber
vials marked “LIDOCAINE” and “WATER”, respectively. The investigator
wore examination gloves while applying the Placebo liquid but not the
Control liquid. During a laboratory visit, the temperature required to
evoke a subjective rating ofmoderate painwas determined, and placebo
analgesia was induced via an expectancy paradigm, as described below.
On two separate days, PET scanswere performed using [18F]fallypride to
quantify D2/D3 receptor availability and how it may differ following
application of the Placebo and Control liquids, respectively.
2.3. Laboratory visit
The laboratory visit (Test day 1) had two parts: part 1, to identify the
temperature of thermal stimulus needed to evoke consistent pain and
induce placebo analgesia via a verbal and experience-based expectancy
procedure; part 2, to measure the placebo response during a painful
thermal stimulation.
2.3.1. Define thermal stimulus profile (Fig. 1A)
The Control solution, which was truthfully identified to the partici-
pant as water, was applied to the left upper or lower volar forearm
(location counterbalanced with that of Placebo across subjects). A ther-
mal stimulus was then delivered continuously for 12 min to the same
location using a temperature contact device (Yale University Bioengi-
neering Department; Eisenberger et al., 2006; Jarcho et al., 2013). Stim-
ulation started at 40 °C, and pain was rated at 15-sec intervals. Ratings
were made by finger press on a button box according to a 0-to-100
(no pain to most pain imaginable) visual analog scale (VAS), which
was displayed on a computer screen in front of the participant. During
each interval, a red bar on the VAS began at 0 and increased by 1
point every 150 ms. The participant was instructed to make a button
press when the bar reached the point on the VAS that described her
current level of pain. The bar remained at that point on the VAS for
the remainder of the 15-sec interval before being reset to 0. Tempera-
ture was adjusted at each interval to maintain a moderate level of
pain, defined as 30–40 on the 0 to 100 VAS scale, with 35 as a target
rating. Ratings 15 points above or below the target rating resulted in a
1.5 °C increase or decrease in temperature; parametrically smaller
adjustments were made as ratings approached 35 VAS. To avoid tissue
damage, the maximum temperature was set to 46 °C.
2.3.2. Expectancy procedure to induce placebo analgesia (Fig. 1B)
The Placebo, characterized as Lidocaine, was applied to a distinct
location of the upper or lower volar forearm (opposite location as the
control). A 3-min continuous thermal stimulus, purportedly at the
average temperature required to evokemoderate pain (i.e., the average
temperature for all intervals with a rating between 30 and 40 VAS), was
then delivered to the same location. To simulate the sensation of analge-
sia, the thermal stimulus was surreptitiously decreased by 3 °C from the
average temperature actually required to evoke moderate pain. This
procedure was performed to reinforce the expectation of analgesia.
Fig. 1.Depiction of experimental methods. An initial laboratory visit included 2 phases, depicted in Panels A and B. (A) Define thermal stimulus profile. A 12-min continuous thermal stim-
ulus was delivered to the same location of the volar forearm where the Control liquid had been applied. Stimulation started at 40 °C, and pain was rated at 25-sec intervals using an elec-
tronic visual analog scale. Temperature was adjusted at each interval to maintain a moderate level of pain. (B) Expectancy procedure and measurement of placebo analgesia. The Placebo,
characterized as Lidocaine, was applied to a distinct location of the volar forearm. To produce the sensation of analgesia, a 3-min continuous thermal stimulus, purportedly the average
temperature required to evokemoderate pain, was then delivered to the same location, but surreptitiously decreased by 3 °C. Prior to receiving the 12-min thermal stimulus profile paired
with Placebo, participants rated howeffective they expected the analgesic treatmentwould be. Thermal stimulationwas delivered to the locationwhere the experienced-based expectancy
procedure had been carried out. Although participants rated their pain at 25-sec intervals, these ratings were now independent of the temperature. Thus, the temperature was held
constant across Control and Placebo conditions while the ratings were allowed to vary. Once the thermal stimulus concluded, participants were asked to report their recalled efficacy of
the analgesic treatment. After their laboratory visit, participants received two PET scans: for one scan the 12-min thermal stimulus profile was paired with the Control (Panel C), for
the other itwas pairedwith the Placebo (order counterbalanced; Panel D). Aswith the laboratory visit, participants rated expected and recalled efficacy of the Placebo prior to and following
thermal stimulation, respectively. They used the electronic visual analog scale to rate their pain at 25-sec intervals during each thermal stimulus.
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Prior to receiving the 12-min thermal-stimulus profile paired with
Placebo, participants rated how effective they expected the analgesic
treatment would be on a 0 to 100 ("not at all" to "entirely") VAS scale.
Thermal stimulation was delivered to the location on the arm that was
involved in the prior experience-based expectation induction. Although
participants rated their pain at 15-sec intervals, the temperature of the
stimulus was no longer adjusted on the basis of these ratings. Instead,
the temperature at each intervalwas set to the temperature determined
by the initial thermal-stimulus profile. Thus, the temperature during
each interval was identical during the Control and Placebo conditions,
while ratings were allowed to vary. Once the thermal stimulus was re-
moved, participants were asked to rate the efficacy of the analgesic
treatment on a 0-to-100 (not at all to entirely) VAS scale.2.4. PET scanning visits
After the laboratory visit (13.13 ± 14.77 days), each participant re-
ceived two PET scans on separate test days: for one scan, the 12-minthermal-stimulus profile was paired with the Control condition
(Fig. 1C); for the other, it was paired with the Placebo condition
(Fig. 1D). The order of scans for Control and Placebo conditions was
counterbalanced. For all participants, scans were performed between 1
and 7 days apart (0.47 ± 3.42 days). One each of the two scan days, the
participantwas aware of the test condition (Placebo or Control) before en-
tering the scanning room. As with the laboratory visit, participants rated
expected and recalled efficacy of the Placebo prior to and following ther-
mal stimulation, respectively. They used the same VAS and button box
to rate their pain at 25-sec intervals during each thermal stimulus.2.5. PET and MR imaging
D2/D3 receptor availability was quantified with the radioligand [-
18F]fallypride, in order to compare the effects of the stimulus complex,
consisting of the label on the vial of purported medication or control
solution, and the fact that the investigator was wearing gloves (Placebo)
or not (Control). Images were acquired using a Siemens ECAT EXACT
HR+ scanner (in-plane resolution full-width at half-maximum
110 J.M. Jarcho et al. / NeuroImage: Clinical 10 (2016) 107–114(FWHM) = 4.6 mm, axial FWHM = 3.5 mm, axial field of view =
15.52 cm) in 3D mode. A 7-min transmission scan was acquired using a
rotating 68Ge/68Ga rod source to obtain data for measured attenuation
correction. Dynamic data were acquired in list mode following a bolus in-
jection of [18F]fallypride (~5 mCi ± 5% in 30 s; specific activity ≥ 1 Ci/
μmol). After 70-min of data acquisition, participants had a 15-min
break, and then returned to the scanner bed. After a second transmission
scan, dynamic data were collected for another 80-min. The total dynamic
scanning sequence consisted of 76-frames acquired during the first scan-
ning block (twelve 30-sec frames followed by sixty-four 1-min frames)
and 80-frames (eighty 1-min frames) acquired during the second block
of scanning. The PlaceboorControl liquidwas applied5-minprior to deliv-
ery of the thermal stimulus (100-min following injection). The thermal
stimulus was applied after the radioligand reached an approximate
steady state in the brain (105-min following injection). Data were recon-
structed using ECAT v7.3 software using the OSEM algorithm (Ordered
Subset Expectation Maximization; 6 iterations, 16 subsets), correcting
for decay, attenuation, and scatter.
On the same day as one of the PET scans, participants underwent
structural magnetic resonance imaging (MRI) with a 1.5-T Siemens
SONATA scanner. A high-resolution sagittal T1-weighted 3D volumetric
scan was acquired using a whole-brain MPRAGE sequence (repetition
time/echo time = 25/11-ms, number of excitations = 1, slice
thickness = 1.2 mm contiguous, in-plane resolution = 1 × 1 mm2).
This anatomical scan was used for data registration in preprocessing,
to improve anatomical localization of PET data.
2.6. Quantification of placebo response
Three aspects of the placebo response were measured by self-report
during the laboratory visit and the PET scans. 1) Expected efficacy was
defined as effectiveness of the analgesic treatment, just before delivery
of the 12-min thermal stimulus paired with Placebo (immediately after
verbal and experience-based procedures during the Laboratory visit).
Participants used a scale from 0 (not at all effective) to 100 (completely
effective) to rate their expectations. 2) Concurrent efficacy was defined
as the difference in average pain ratings provided at 25-sec intervals
during the 12-min thermal stimulation paired with the Placebo relative
to Control conditions. 3) Recalled efficacy was defined by ratings about
the effectiveness of the analgesic treatment immediately following
the 12-min thermal stimulus paired with Placebo. Participants used a
0- (not at all effective) to 100-point (completely effective) scale to
rate the efficacy of the purported treatment.
Separate one-sample t-tests were used to determine whether
expected efficacy and recalled efficacy differed significantly from a
rating of 0 (not at all effective). Concurrent efficacy was tested using a
paired sample t-test to assess the difference in average pain ratings
when the thermal stimuluswas pairedwith Placebo vs.Control. Separate
paired sample t-testswere used to determinewhether themagnitude of
placebo response differed during the laboratory visit and PET assess-
ments. The relationship among expected efficacy, concurrent efficacy,
and recalled efficacy were assessed with Spearman's Rho (ρ) tests due
to the small size of the sample.
Statistical analyses for all behavioral data relied on 2-tail tests, and
were conducted with SPSS (IBM Corp. Released 2013. IBM SPSS Statis-
tics for Macintosh, Version 22.0. Armonk, NY: IBM Corp).
2.7. Quantification of D2/D3 receptor availability
Preprocessing for PET data was carried out with PMOD software v3.2
(PMOD Technologies Ltd, Zurich, Switzerland). Short-duration frames
were binned together to generate a series of 10-min frames. Thus, the
first scanning block comprised frames 1–7, and the second scanning
block comprised frames 8–15. For scans in both the Placebo and Control
conditions, thermal stimulationwas initiated during the second scanning
block, at the start of frame 10. Amean imagewas then generated using all15 averaged frames. To correct for motion, each of the averaged frames
was then realigned to a mean image. Motion-corrected PET data from
eachparticipantwere co-registered to those fromher structuralMRI scan.
Whole-brain BPND maps were used to quantify D2/D3 dopamine
receptor availability (i.e., binding potential, BPND) in the Placebo and Con-
trol conditions. These maps were generated for each participant using a
two-step process implemented with the Pixel-wise Kinetic Modeling
Tool in PMOD (PMOD Technologies Ltd). In the first step, a simplified
reference-tissue model (SRTM) (Lammertsma and Hume, 1996), was
used to determine k2′ estimates and generate time-activity curves
(TACs) from one region of interest (ROI) with a high level of receptor
availability, in this case the striatum (comprised of nucleus accumbens,
caudate, and putamen), and another with negligible receptor expression,
in this case the cerebellum (Mukherjee et al., 2002), to serve as a refer-
ence tissue. Bilateral striatal ROIs were delineated on each participant's
anatomicalMRI using FMRIB [functionalMRI of the brain] Integrated Reg-
istration and Segmentation Tool [FIRST], a template-based method in FSL
[FMRIB Software Library] (Oxford University, Oxford UK). Unlike the stri-
atum, the cerebellum has negligible and homogeneous D2/D3 dopamine
receptor availability (Mukherjee et al., 2002). As such, cerebellar TACs can
be derived from several consecutive slices,which reflect D2/D3 dopamine
receptor binding in the structure as awhole. Bilateral cerebellar ROIswere
manually delineated with cylindrical volumes (diameter = 15 mm;
height=5mm)placed in themiddle of the cerebellum to avoid potential
artifacts introduced at CSF/grey matter intersections. In the second step,
ROIswere transferred to the co-registered PET data, where TACswere ex-
tracted and entered, along with the fixed k2′ estimate obtained in step
one, into an SRTM2 (Wu and Carson, 2002) pixel-wise analysis that pro-
duced a whole-brain BPND map for each participant. This analysis as-
sumed that BPND was constant throughout the scan, with negligible
effects of the thermal stimulation, whichwas applied 105min after injec-
tion. Indeed, no change in TACs was observed in response to thermal
stimulation in any of the subcortical regions assessed (caudate nucleus,
putamen, nucleus accumbens, amygdala, hippocampus, and thalamus;
data not shown). As such, the analysis tested the effect of the stimulus
complex, including knowledge that PET scans would be acquired in the
Placebo or Control conditions, respectively.
StructuralMRI datawere normalized into theMNI (Montreal Neuro-
logical Institute) template space using SPM8 (WellcomeTrust Centre for
Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm), and the transforma-
tion parameters were then applied to the coregistered whole-brain
BPND maps. BPND maps were then smoothed with a Gaussian filter to
8-mm FWHM.2.8. Dopamine D2/D3 receptor availability and the placebo response
Awhole-brain analysiswas performedwith SPM8.Main effects of Pla-
cebo on dopamine D2/D3 receptor BPND were first assessed with a paired
t-test; scan orderwas included as a covariate. Since fewprior studies have
tested the relationship between extrastriatal dopaminergic markers and
the placebo response, we used a relatively liberal statistical threshold
for testing these effects. We took this approach so that results from this
preliminary study can be used to help generate hypotheses for future
work on the relationship between placebo analgesia and dopaminergic
function. Statistical significance was therefore set using a combined un-
correctedheight threshold of p b 0.005with a 100-voxel extent threshold.
Clusters with significant differences in BPNDwere subjected to explor-
atory correlation analyses with measures of placebo response. To do this,
a spherewith a 5-mmradiuswas drawnaround the peak voxel of clusters
with significant differences in BPND. Average BPND values across this
sphere were extracted for each participant's MNI-space data, and
imported to SPSS. Spearman's Rho (ρ) tests were used to determine
whether changes in BPND were correlated with expected, concurrent, or
recalled placebo efficacy. A threshold of p = 0.017 was needed to reach
significance after Bonferroni correction for performing three tests.
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also assessed using effect-size maps, which provide a comparison of
differences in BPND that did not reach the prescribed statistical thresh-
old. Effect-size maps (Cohen's d) with a threshold of d N 0.20 (which
corresponds with a small effect size) were created by taking the square
root of the mean difference in intensity of whole-brain BPND maps
obtained in Control scans to whole-brain BPNDmaps obtained in Placebo
scans, divided by the pooled standard deviation of the difference values.
3. Results
3.1. Placebo response (see Table 1)
The average temperature required tomaintainmoderate pain across
the 12-min thermal stimulus was 44.57 °C (SD = 1.08 °C).
3.1.1. Expected efficacy
Participants expected the placebo to be highly effective during both
Laboratory and PET testing visits. A paired sample t-test showed no
difference in expected efficacy during Laboratory versus PET visits
(t(14) = 1.03, p = 0.32), but self-reports of expected efficacy during
Laboratory and PET visits were not significantly correlated (ρ = 0.31,
p = 0.26).
3.1.2. Concurrent efficacy
During the Laboratory visit, average on-line pain ratings were lower
when the thermal stimulus was paired with the placebo relative to the
control, indicating a significant placebo analgesic effect (t(14) = 3.33,
p = 0.005). There was no difference in concurrent efficacy across PET
visits (t(14) =−1.07, p = 0.31). Further analyses were completed to
help clarify whether the absence of concurrent placebo effects across
PET visits was due to ratings obtained during the Control condition or
Placebo condition. Paired sample t-tests showed while there was no
difference in average pain ratings during Laboratory and PET testing
visits when the thermal stimulus was paired with placebo (t(14) =
0.14, p = 0.89), pain ratings were significantly lower during the PET,
relative to Laboratory, visit when the thermal stimulus was paired
with control (t(14)= 3.91, p= 0.002). Concurrent efficacy during Lab-
oratory and PET visits were positively correlated (ρ=0.69, p = 0.006).
3.1.3. Recalled efficacy
Participants recalled the placebo as being highly effective during
both Laboratory and PET visits. A paired sample t-test showed no differ-
ence in recalled efficacy during Laboratory or PET visits (t(14) = 0.16,
p = 0.88); and recalled efficacy during Laboratory and PET visits were
significantly positively correlated (ρ= 0.63, p = 0.02).
3.1.4. Relationship between three forms of placebo response
During the Laboratory visit, concurrent, and recalled placebo efficacy
were unrelated. During the Placebo PET visit, expected and recalled
efficacy were highly correlated (ρ= 0.68, p = 0.005), but concurrentTable 1
Placebo response across Laboratory and PET visits.
Laboratory PET
Mean SD Mean SD
Predicted efficacya 53.67 32.81⁎⁎⁎ 43.33 32.16⁎⁎⁎
Concurrent Efficacy (Placebo–Control)b −10.38 12.11⁎⁎ 2.93 10.56ns
Average ratings with Placebo 23.38 11.01 22.82 17.95
Average ratings with Control 33.70 3.91 19.9 13.4
Recalled efficacya 47.50 29.40⁎⁎⁎ 45.13 38.55⁎⁎
ns p N 0.05 not significant.
a One-sample t-tests: reported efficacy of placebo comparedwith 0 (not effective at all).
b Paired sample t-tests: average ratings for stimulus paired with placebo vs. control.
⁎⁎ p b 0.005.
⁎⁎⁎ p b 0.001.efficacy was not related either to expected or to recalled efficacy. Nota-
bly, themore days that elapsed from the laboratory visit, the lowerwere
the levels of expected efficacy during the Placebo PET visit (ρ=−0.62;
p = 0.01). Exploratory analyses determined that none of the three
forms of placebo response during the Laboratory visit were associated
with expected efficacy during the subsequent Placebo PET visit.
3.2. Dopamine release and the placebo response
In a whole-brain analysis, there was higher BPND (less DA) in left
vlPFC for Control relative to Placebo scans (x, y, z coordinates: −29,
30, −14; ke = 507; t(14) = 3.12, p = 0.001 uncorrected) (Fig. 2A).
This effect did not retain statistical significance after familywise correc-
tion for number of comparisons. No differences were observed for the
contrast of Placebo N Control.
Exploratory analyses revealed that the greater change in left vlPFC
BPND for Control, relative to Placebo scans, the greater the recalled placebo
efficacy (ρ= 0.58, p = 0.022; Fig. 2B). However, results did not remain
significant after Bonferroni correction for the three types of self-
reported efficacy. There was no significant relationship between the
change in BPND with expected or concurrent efficacy, nor was there a re-
lationship between BPND, measures obtained during the laboratory visit,
or number of days that elapsed between laboratory and PET visits.
Effect size maps (Cohen's d N 0.2) demonstrated that while differ-
ences in striatal BPND for Control relative to Placebo scans did not reach
the prescribed statistical threshold, there were medium-size effects in
this region. Medium to large effects also emerged in the thalamus,
hippocampus, insula, and dorsal anterior cingulate (Fig. 3).
4. Discussion
In this study, three forms of placebo responseweremeasured during
laboratory and PET scanning. Expected and recalled placebo efficacy
occurred at equally high levels across both visits. Concurrent efficacy
was only observed during the laboratory visit. Dopamine D2/D3 recep-
tor availability was lower in left vlPFC when the stimulus complex for a
topical placebo analgesic was present during noxious thermal stimula-
tion compared to a control stimulus complex. The degree to which
receptor availability was higher in left vlPFC in the Control than the
Placebo conditionwas associatedwith higher levels of recalled analgesic
efficacy. While derived from a small sample, these results support re-
search that suggests the dopamine system plays important role in me-
diating placebo effects (e. g., Boileau et al., 2007; Brody et al., 2009; de
la Fuente-Fernández et al., 2001, 2002; Haltia et al., 2008; Kaasinen
et al., 2004; Kim et al., 2008; Lidstone et al., 2010; Martikainen et al.,
2005; Oswald et al., 2005; Scott et al., 2007, 2008; Strafella et al.,
2006), and provide further insight into the psychological and neuro-
pharmacological mechanisms that promote placebo analgesia.
Pain is a subjective experience. Thus, the method used to measure
placebo analgesia may affect the magnitude of self-reported placebo
effects. In this study, relatively high levels of placebo analgesia were
obtainedwithmeasures of expected and recalled efficacy. However, ex-
pected efficacy during the Placebo PET scan was negatively correlated
with the number of days that had elapsed from the laboratory visit.
This suggests that temporal factors related to prior experience may
influence some measures of placebo response. Hints of other temporal
influences on placebo effects also emerged. For instance, there was a
lack of continuity between all three forms of placebo response during
the initial laboratory visit, yet high levels of continuity for expected
and recalled efficacy during PET scanning. Thus, some form of
experience-related consolidation may occur during the initial laborato-
ry visit that influences the subsequent experience of placebo analgesia.
Concurrent efficacy, calculated as the difference betweenonline pain
ratings when the 12-min thermal stimulus was paired with placebo,
relative to control, was only observed during the laboratory visit. Closer
inspection of the data shows thatwhen the thermal stimuluswas paired
Fig. 2.Dopaminergic changes related to placebo effects. (A). Awhole brain analysis demonstrated significantly greater binding potential (less DA) in left vlPFC (−29, 30,−14) for Control,
relative to Placebo, scans. (B). A positive slope on the scatter plot reflects greater recalled placebo efficacy is associatedwith higher BP (less DA) in left vlPFC for Control, relative to Placebo,
scans.
112 J.M. Jarcho et al. / NeuroImage: Clinical 10 (2016) 107–114with placebo, participants made equally low ratings during clinic and
PET visits. However, when the thermal stimulus was paired with the
control condition, significantly higher ratings were provided in the
laboratory than in the PET environment. This suggests that factors unre-
lated to placebo analgesia may have modulated pain during the control
scan (e.g., anxiety for painful stimulations).
Therewasweak evidence for a role of prefrontal cortical dopaminer-
gic transmission in placebo analgesia. Specifically, dopamine D2/D3
receptor availability was lower in left vlPFC when analgesia was antici-
pated, suggesting that prefrontal cortical dopamine release occurred.
These findings correspond with fMRI studies that, using similar experi-
mental methods, show the vlPFC is engaged by placebo analgesia and is
related to placebo efficacy (Wager et al., 2004, 2011; Watson et al.,
2009). In thatwork, as with in the current study, thememory of placebo
efficacy was established during an initial testing session, and then
retrieved and evaluated in light of stimuli delivered during the neuro-
imaging phase of the experiment. This reflects one of the primary func-
tions of dopaminergic transmission in PFC, which is to maintain
memory representations and update them at appropriate times
(reviewed by Seamans and Robbins, 2010). Thus dopaminergicFig. 3. Effect size of dopaminergic changes related to placebo effects. Whole brain maps depic
stimulation was pairedwith Control relative to Placebo. Overall lower levels of binding, suggestitransmission in PFC may help promote placebo analgesia by maintaining
memory of treatment efficacy and updating beliefs about that efficacy.
An effect-size analysis demonstrated that dopamine D2/D3 BPND
was reduced in a widespread network of brain regions often implicated
in nociception and placebo analgesia (Apkarian et al., 2005; Atlas and
Wager, 2014; Garcia-Larrea and Peyron, 2013; Peyron et al., 2000),
including striatum, dorsal anterior cingulate, thalamus, hippocampus
and insula alongwith vlPFC. Failure to reach prescribed statistical signif-
icance, particularly in the striatum, may be related to the small sample
size, methodological differences with prior work, and/or limitations in
the design of the current study. For instance, in prior PET studies that
find a relationship between placebo analgesia and striatal dopamine
transmission (Scott et al., 2007, 2008), participants learned about the
effectiveness of the placebo while undergoing PET scanning, without
the opportunity to form experience-based expectations about the
placebo's efficacy. Given that the striatumplays an integral role in learn-
ing, thesefindings are not unexpected. In the present study, participants
formed experience-based expectations about the placebo's efficacy
during their initial laboratory visit. Thus, unlike prior work, participants
had already learned about the effectiveness of the placebo before tot effect size (Cohen's d) for change in binding potential during PET scans where thermal
ve of greater endogenous DA, are observed throughout the brain for the Placebo condition.
113J.M. Jarcho et al. / NeuroImage: Clinical 10 (2016) 107–114undergoing PET scanning. Because of this, dopamine transmission may
have been more closely related to the implicit or explicit recall of previ-
ously learned relationships, which is commonly associated with en-
gagement of vlPFC (Badre and Wagner, 2007; Long et al., 2010;
Murray and Ranganath, 2007). This suggests that the vlPFC may play a
critical role in promoting placebo analgesia, once the relationship
between a placebo and the experience of analgesia has been learned.
Future work that differentiates the neural mechanisms implicated in
promoting suggestion and learning-based analgesia as they differ from
the recall of learned associations is critical.
Alternatively kinetics of the radioligand used in the present study in
conjunction with the length of PET scanning may have contributed to a
failure to observe statistically significant effects in the striatum. Prior
PET studies assessed the relationship between DA system function and
placebo effects using [11C]raclopride (Scott et al., 2007, 2008). This
radiotracer has relatively rapid kinetics and uptake/washout properties
that make it well suited to measure BP in brain regions with a high
density of D2/D3 receptors, such as the striatum, but largely precludes
the reliable measurement of BP in brain regions with a low density of
D2/D3 receptors, such as the cortex (Farde et al., 1987; Kohler et al.,
1985). [18F]fallypride has relatively slow kinetics and uptake/washout
properties that make it well suited to measure BP in brain regions
with both high and low density D2/D3 receptors (Zald et al., 2010).
However, the rate of uptake andwashout of [18F]fallypride varies across
brain regions depending on D2/D3 receptor density. In regionswith low
D2/D3 receptor density, uptake andwashout occurmore rapidly than in
regions with high D2/D3 receptor density. Thus, the duration of
scanning (165 min from tracer injection to the end of scanning) may
have been sufficient to obtain a reliable signal in vlPFC (low D2/D3
receptor density), it may have been insufficient to obtain a reliable
signal in the striatum (high D2/D3 receptor density). Some argue that
a scan duration of 3–4 h is necessary for [18F]fallypride to achieve
maximal stability in the striatum (Kegeles et al., 2008; Mukherjee
et al., 2002), while others suggest such long-duration scans are optimal
for studies that include a task-based experimental manipulation
(Ceccarini et al., 2012). Follow-up studiesmay be better able to simulta-
neously detect effects of placebo analgesia on DA function in cortical
and striatal regions by implementing longer [18F]fallypride PET scans.
The study had two additional limitations. First, only women were
assessed. Although a preponderance of evidence demonstrates gender
differences in nociceptive processing, the mechanisms driving this
difference remain unclear (Mogil, 2012). Given the limited sample size
of this preliminary study, it was not possible to assess a sufficient num-
ber ofmen andwomen tomakemeaningful conclusions about potential
gender effects. Since more women than men suffer from chronic pain
syndromes (Mogil, 2012), we sought to maximize the potential clinical
impact of this work by specifically studying women. Follow-up studies
with a larger sample size should include men and women to
determine whether results are generalizable, or if gender-based differ-
ences emerge. A second limitation is that the thermal stimulus profile
was defined in the context of the Control condition. This replicates
well-tested methods used in prior studies relating brain function to
placebo analgesia (Wager et al., 2004); however, defining the thermal
stimulus profile independently, during a separate laboratory visit, may
optimize this design. By implementing this change, order of Control
and Placebo conditions could then be counterbalanced during the
laboratory visit in which the expectation manipulation is performed.
Despite these limitations, taken together, these findings are consis-
tent with an important role of cortical dopaminergic transmission in
modulating specific forms of placebo analgesia. They provide initial
evidence that dopamine transmission in vlPFC modulates learning-
based placebo analgesia. Further work is needed to determine whether
learned, compared with verbally induced expectation of placebo
analgesia is associated with distinct pathways of DA transmission.
Finally, these results underscore the need to carefully consider how
self-reported symptom improvement is assessed in clinical settings.Conflict of interest
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